BeiGene Initiates Ph III Trial of PD-1 Inhibitor Tislelizumab + Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer in China

BeiGene Initiates Ph III Trial of PD-1 Inhibitor Tislelizumab + Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer in China

Source: 
CP Wire
snippet: 
  • Tislelizumab is a monoclonal antibody PD-1 checkpoint inhibitor
  • BeiGene and Celgene have a global collaboration agreement for the development of tislelizumab outside of Asia (except Japan)